Bradford Dickerson, MD
Neurology · Boston, MANPI 1184615700
Payments from drug & device makers
Across 40 payments — averaging $3099.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$66K
- Eli Lilly$24K
- Eisai Inc.$8K
- Novo Nordisk AS$6K
- Biogen$6K
- Acadia Pharmaceuticals Inc$6K
- plus $9K from 6 others
What the payments were for
- Consulting fees$53,25795%
- Speaking & faculty fees$1,5753%
- Travel & lodging$1,2982%
- Food & beverage$250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 5 | $65,642 |
| Eli Lilly | 8 | $24,080 |
| Eisai Inc. | 4 | $7,920 |
| Novo Nordisk AS | 3 | $6,064 |
| Biogen | 4 | $5,906 |
| Acadia Pharmaceuticals Inc | 3 | $5,800 |
| Merck | 2 | $1,976 |
| Genentech, Inc. | 1 | $1,800 |
| Novo Nordisk | 1 | $1,628 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 1 | $1,575 |
| Janssen Research & Development, LLC | 7 | $1,100 |
| Vertex | 1 | $492 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$123,982 in reported general payments places this provider in the 80th percentile of 761 neurology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Memantine Hcl ErMemantine Hcl | 31 | $5,825 |
| Memantine Hcl | 24 | $2,750 |
| Galantamine ErGalantamine Hbr | 12 | $1,066 |
| Donepezil Hcl | 76 | $1,061 |
| Sertraline Hcl | 20 | $664 |
| Escitalopram Oxalate | 13 | $310 |
| Trazodone Hcl | 16 | $144 |
| Citalopram HbrCitalopram Hydrobromide | 24 | $126 |
| Risperidone | 12 | $121 |
Paid to pharmacies, not to this prescriber.
Other neurology in Boston
- Stephanie RutrickBoston$31.4M
- Scott PlotkinBoston$26.3M
- Patrick WenBoston$18.2M
- James BerryBoston$8.9M
- Isabel Arrillaga-RomanyBoston$8.2M
- Mahmut GurolBoston$7.4M
- Gad MarshallBoston$6M
- Shawn MurphyBoston$5.9M
- Suma BabuBoston$5.8M
- Luis Gonzalez CastroBoston$5.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.